The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] crizotinib results in decreased activity of ABCB1 protein
crizotinib results in decreased phosphorylation of AKT1 protein EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]
ALK gene mutant form results in decreased susceptibility to crizotinib; ALK gene SNP results in decreased susceptibility to crizotinib; ALK protein mutant form results in decreased susceptibility to crizotinib ALK protein affects the susceptibility to crizotinib [ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to Crizotinib; [Crizotinib results in increased mutagenesis of ALK gene mutant form] which results in decreased susceptibility to Crizotinib; [Crizotinib results in increased mutagenesis of ALK protein mutant form] which results in decreased susceptibility to Crizotinib; [Crizotinib results in increased mutagenesis of ALK protein mutant form] which results in increased activity of ALK protein; [Ethylnitrosourea results in increased mutagenesis of ALK protein] inhibits the reaction [Crizotinib results in decreased phosphorylation of ALK protein]; [Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to Crizotinib; ALK gene SNP inhibits the reaction [Crizotinib results in decreased phosphorylation of ALK protein mutant form]; ALK protein mutant form inhibits the reaction [Crizotinib binds to and results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [Crizotinib results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [Crizotinib results in decreased phosphorylation of ALK protein]; Crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; Crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein]; Crizotinib results in decreased phosphorylation of and results in decreased activity of ALK protein mutant form Crizotinib results in decreased activity of ALK protein; Crizotinib results in decreased activity of ALK protein mutant form crizotinib results in decreased phosphorylation of ALK protein; crizotinib results in decreased phosphorylation of ALK protein mutant form crizotinib results in decreased stability of ALK protein mutant form crizotinib results in increased mutagenesis of ALK gene mutant form; crizotinib results in increased mutagenesis of ALK protein mutant form crizotinib results in decreased activity of ALK protein mutant form
crizotinib results in increased expression of BCL2L11 protein BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased expression of BCL2L11 protein] BCL2L11 protein affects the susceptibility to crizotinib
crizotinib results in decreased expression of BIRC2 protein MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC2 protein]
crizotinib results in decreased expression of BIRC5 protein MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC5 protein]
BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased cleavage of CASP3 protein] [crizotinib co-treated with 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one] results in increased cleavage of CASP3 protein crizotinib results in increased activity of CASP3 protein
crizotinib results in decreased expression of CDA protein [crizotinib results in decreased expression of CDA protein] which results in increased susceptibility to gemcitabine
[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein
EGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of AKT1 protein]; EGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to Crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to Crizotinib] EGF protein results in decreased susceptibility to crizotinib
EGFR protein mutant form results in decreased susceptibility to crizotinib; EGFR protein results in decreased susceptibility to crizotinib [EGFR protein results in increased phosphorylation of EGFR protein] which results in decreased susceptibility to crizotinib; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]
crizotinib results in decreased stability of EML4 protein mutant form [crizotinib results in increased mutagenesis of EML4 gene mutant form] which results in decreased susceptibility to crizotinib
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]
EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]
[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]
[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]
[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]
crizotinib results in decreased activity of MET protein MET protein affects the susceptibility to Crizotinib MET gene mutant form results in increased susceptibility to crizotinib crizotinib results in increased mutagenesis of MET protein [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [Crizotinib results in increased mutagenesis of MET protein] inhibits the reaction [Crizotinib binds to and results in decreased activity of MET protein]; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Crizotinib binds to and results in decreased activity of MET protein; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MET protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of STAT3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BCL2L11 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BIRC2 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BIRC5 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of XIAP protein]
Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein]
Crizotinib results in increased cleavage of PARP1 protein benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Crizotinib results in increased cleavage of PARP1 protein]
crizotinib results in decreased phosphorylation of STAT3 protein [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of STAT3 protein]
EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]
crizotinib results in decreased expression of XIAP protein MET gene mutant form promotes the reaction [crizotinib results in increased expression of XIAP protein]
browse the term
